Coverage for the indication versus for the drug

Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable.

The question about coverage that I actually want answered is the second one below. The first is context and I have kept it short.

Both are stated with units, and I have said what I already checked so that nobody repeats it.

Where coverage was granted, saying what the successful submission contained is one of the more useful posts on the site.

Coming back to post #33, because the follow-up matters more than the original answer.

Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.

Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves surprise at the pharmacy.

Summarising the coverage thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

Where coverage was granted, saying what the successful submission contained is one of the more useful posts on the site.

It is worth stating the boring hypothesis before the interesting one.

Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and appeals based on the covered indication work better.

Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.

Post #76 describes the usual case. This is about the unusual one.

Keep every document with dates in one place. An appeal months later is assembled from whatever you kept.

I am describing what is, rather than arguing for what should be.